Analysts Set Medexus Pharmaceuticals Inc. (TSE:MDP) Price Target at C$5.49

Shares of Medexus Pharmaceuticals Inc. (TSE:MDP) have earned an average rating of “Buy” from the seven research firms that are currently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation, one has issued a buy recommendation and four have given a strong buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is C$5.49.

Several research analysts have recently weighed in on MDP shares. Alliance Global Partners upgraded Medexus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, December 23rd. Raymond James raised Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 target price for the company in a research report on Wednesday, January 8th. Stifel Nicolaus cut shares of Medexus Pharmaceuticals from a “buy” rating to a “hold” rating and lowered their target price for the company from C$6.00 to C$3.45 in a research note on Friday, February 7th. Stifel Canada lowered shares of Medexus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 6th. Finally, Ventum Cap Mkts upgraded shares of Medexus Pharmaceuticals to a “strong-buy” rating in a research report on Friday, January 17th.

Medexus Pharmaceuticals Price Performance

MDP opened at C$2.12 on Friday. Medexus Pharmaceuticals has a 1 year low of C$1.47 and a 1 year high of C$5.56. The stock has a 50-day moving average price of C$2.70 and a 200-day moving average price of C$2.89. The firm has a market cap of C$47.46 million, a PE ratio of 10.14 and a beta of 1.96.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.